Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

HMGB1 Protein Interactions in Prostate and Ovary Cancer Models Reveal Links to RNA Processing and Ribosome Biogenesis through NuRD, THOC and Septin Complexes

  • Barreiro-Alonso, Aida
  • Lamas, Mónica
  • Lorenzo-Catoira, Lidia
  • Pardo, Mercedes
  • Yu, Lu
  • Choudhary, Jyoti
  • Cerdán, María Esperanza
[Abstract] This study reports the HMGB1 interactomes in prostate and ovary cancer cells lines. Affinity purification coupled to mass spectrometry confirmed that the HMGB1 nuclear interactome is involved in HMGB1 known functions such as maintenance of chromatin stability and regulation of transcription, and also in not as yet reported processes such as mRNA and rRNA processing. We have identified an interaction between HMGB1 and the NuRD complex and validated this by yeast-two-hybrid, confirming that the RBBP7 subunit directly interacts with HMGB1. In addition, we describe for the first time an interaction between two HMGB1 interacting complexes, the septin and THOC complexes, as well as an interaction of these two complexes with Rab11. Analysis of Pan-Cancer Atlas public data indicated that several genes encoding HMGB1-interacting proteins identified in this study are dysregulated in tumours from patients diagnosed with ovary and prostate carcinomas. In PC-3 cells, silencing of HMGB1 leads to downregulation of the expression of key regulators of ribosome biogenesis and RNA processing, namely BOP1, RSS1, UBF1, KRR1 and LYAR. Upregulation of these genes in prostate adenocarcinomas is correlated with worse prognosis, reinforcing their functional significance in cancer progression., This research was funded by the Wellcome Trust (grant no. 206194/Z/17/Z) and by Plan Estatal I+D+i, Instituto Carlos III (ISCIII, Spain) (grants no. PI14/01031 and PI18/01417) cofunded by the Fondo Europeo de Desarrollo Regional-FEDER (The European Regional Development Fund-ERDF) “A way of Making Europe”, and by Xunta de Galicia (Consolidación Grupos Referencia Competitiva grant no. ED431C 2020-08), Reino Unido. Wellcome Trust; 206194/Z/17/Z, Xunta de Galicia; ED431C 2020-08
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Differential Characteristics of HMGB2 Versus HMGB1 and their Perspectives in Ovary and Prostate Cancer

  • Cámara-Quílez, M.
  • Barreiro-Alonso, Aida
  • Rodríguez-Belmonte, Esther
  • Quindós-Varela, María
  • Cerdán, María Esperanza
  • Lamas, Mónica
This is an accepted version of the published document. This version of the article has been accepted for publication, after peer review, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The published manuscript is available at EurekaSelect via https://doi.org/10.2174/0929867326666190123120338., [Abstract] We have summarized common and differential functions of HMGB1 and HMGB2 proteins with reference to pathological processes, with a special focus on cancer. Currently, several “omic” approaches help us compare the relative expression of these 2 proteins in healthy and cancerous human specimens, as well as in a wide range of cancer-derived cell lines, or in fetal versus adult cells. Molecules that interfere with HMGB1 functions, though through different mechanisms, have been extensively tested as therapeutic agents in animal models in recent years, and their effects are summarized. The review concludes with a discussion on the perspectives of HMGB molecules as targets in prostate and ovarian cancers., This work has been funded by the Project Nº PI14/01031, integrated into the National Plan for Sci- entific Research, Development and Technological Innovation 2013-2016 of the ISCIII - General Sub- direction of Assessment and Promotion of the Research – European Regional Development Fund (FEDER) “A way of making Europe”. Funding is also acknowledged by Xunta de Galicia (Consolidación Grupos Referencia Competitiva; Contract No. ED431C 2016-012), Xunta de Galicia; ED431C 2016-012
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

The HMGB1-2 Ovarian Cancer Interactome: the Role of HMGB Proteins and Their Interacting Partners MIEN1 and NOP53 in Ovary Cancer and Drug-Response

  • Cámara-Quílez, M.
  • Barreiro-Alonso, Aida
  • Vizoso-Vázquez, Ángel
  • Rodríguez-Belmonte, Esther
  • Quindós-Varela, María
  • Lamas, Mónica
  • Cerdán, María Esperanza
[Abstract] High mobility group box B (HMGB) proteins are overexpressed in different types of cancers such as epithelial ovarian cancers (EOC). We have determined the first interactome of HMGB1 and HMGB2 in epithelial ovarian cancer (the EOC-HMGB interactome). Libraries from the SKOV-3 cell line and a primary transitional cell carcinoma (TCC) ovarian tumor were tested by the Yeast Two Hybrid (Y2H) approach. The interactome reveals proteins that are related to cancer hallmarks and their expression is altered in EOC. Moreover, some of these proteins have been associated to survival and prognosis of patients. The interaction of MIEN1 and NOP53 with HMGB2 has been validated by co-immunoprecipitation in SKOV-3 and PEO1 cell lines. SKOV-3 cells were treated with different anti-tumoral drugs to evaluate changes in HMGB1, HMGB2, MIEN1 and NOP53 gene expression. Results show that combined treatment of paclitaxel and carboplatin induces a stronger down-regulation of these genes in comparison to individual treatments. Individual treatment with paclitaxel or olaparib up-regulates NOP53, which is expressed at lower levels in EOC than in non-cancerous cells. On the other hand, bevacizumab diminishes the expression of HMGB2 and NOP53. This study also shows that silencing of these genes affects cell-viability after drug exposure. HMGB1 silencing causes loss of response to paclitaxel, whereas silencing of HMGB2 slightly increases sensitivity to olaparib. Silencing of either HMGB1 or HMGB2 increases sensitivity to carboplatin. Lastly, a moderate loss of response to bevacizumab is observed when NOP53 is silenced., This work has been funded by the Projects Nº PI14/01031 and PI18/01714, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 of the ISCIII- General Subdirection of Assesment and Promotion of the Research – European Regional Development Fund (FEDER) “A way of making Europe”. Funding is also acknowledged from Xunta de Galicia (Consolidación Grupos Referencia Competitiva Contract no. ED431C 2016–012). Aida Barreiro-Alonso was funded by a predoctoral fellowship from Xunta de Galicia-2013 (Spain) cofinanced by FEDER, Xunta de Galicia; ED431C 2016–012
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Thanksgiving to Yeast, the HMGB Proteins History from Yeast to Cancer [Review]

  • Lamas, Mónica
  • Vizoso-Vázquez, Ángel
  • Barreiro-Alonso, Aida
  • Cámara-Quílez, M.
  • Cerdán, María Esperanza
This article belongs to the Special Issue Yeasts Biochemistry and Biotechnology, [Abstract] Yeasts have been a part of human life since ancient times in the fermentation of many natural products used for food. In addition, in the 20th century, they became powerful tools to elucidate the functions of eukaryotic cells as soon as the techniques of molecular biology developed. Our molecular understandings of metabolism, cellular transport, DNA repair, gene expression and regulation, and the cell division cycle have all been obtained through biochemistry and genetic analysis using different yeasts. In this review, we summarize the role that yeasts have had in biological discoveries, the use of yeasts as biological tools, as well as past and on-going research projects on HMGB proteins along the way from yeast to cancer., This research was funded by Plan Estatal I+D+i, Instituto de Salud Carlos III (ISCIII, Spain) (grant nos. PI14/01031 and PI18/01417) and Ministerio de Ciencia e Innovación (grant no. PID2021-124564OB-I00), and cofunded by the Fondo Europeo de Desarrollo Regional-FEDER (The European Regional Development Fund-ERDF) “A way of Making Europe” and by Xunta de Galicia (Consolidación Grupos Referencia Competitiva grant no. ED431C 2020-08), Xunta de Galicia; ED431C 2020-08
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Delineating the HMGB1 and HMGB2 Interactome in Prostate and Ovary Epithelial Cells and Its Relationship With Cancer

  • Barreiro-Alonso, Aida
  • Lamas, Mónica
  • García Díaz, Rosa
  • Rodríguez-Belmonte, Esther
  • Yu, Lu
  • Pardo, Mercedes
  • Choudhary, Jyoti
  • Cerdán, María Esperanza
[Abstract] High Mobility Group B (HMGB) proteins are involved in cancer progression and in cellular responses to platinum compounds used in the chemotherapy of prostate and ovary cancer. Here we use affinity purification coupled to mass spectrometry (MS) and yeast two-hybrid (Y2H) screening to carry out an exhaustive study of HMGB1 and HMGB2 protein interactions in the context of prostate and ovary epithelia. We present a proteomic study of HMGB1 partners based on immunoprecipitation of HMGB1 from a non-cancerous prostate epithelial cell line. In addition, HMGB1 and HMGB2 were used as baits in yeast two-hybrid screening of libraries from prostate and ovary epithelial cell lines as well as from healthy ovary tissue. HMGB1 interacts with many nuclear proteins that control gene expression, but also with proteins that form part of the cytoskeleton, cell-adhesion structures and others involved in intracellular protein translocation, cellular migration, secretion, apoptosis and cell survival. HMGB2 interacts with proteins involved in apoptosis, cell motility and cellular proliferation. High confidence interactors, based on repeated identification in different cell types or in both MS and Y2H approaches, are discussed in relation to cancer. This study represents a useful resource for detailed investigation of the role of HMGB1 in cancer of epithelial origins, as well as potential alternative avenues of therapeutic intervention., Funding is acknowledged both from the Instituto de Salud Carlos III under Grant Agreement AES-2014 no. PI14/01031 and from Xunta de Galicia (Consolidación Grupos Referencia Competitiva Contract no. ED431C 2016–012), both co-financed by FEDER. Aida Barreiro-Alonso was funded by a predoctoral fellowship from Xunta de Galicia-2013 (Spain). This work was supported by the Wellcome Trust [grant number WT098051], Xunta de Galicia; ED431C 2016–012, Wellcome Trust (Londres); WT098051